Document Detail


Progress in endocrine approaches to the treatment and prevention of breast cancer.
MedLine Citation:
PMID:  21982237     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Tamoxifen had been the only available hormonal option for the systemic treatment for breast cancer from 1973 to 2000. Enormous efforts have led to the development of potent and selective third generation aromatase inhibitors including anastrozole, letrozole and exemestane. Due to their superior efficacy to tamoxifen, aromatase inhibitors are presently approved as first line agents for the treatment of advanced estrogen receptor (ER) positive breast cancer and adjuvant therapy in early ER positive early breast cancer in postmenopausal women. Selective ER Modulators (SERMS), tamoxifen and raloxifene are the only agents presently used in breast cancer prevention in high risk women and their use has increased substantially over the last decade. Third generations SERMS, lasofoxifene and bazedoxifene have shown significant reduction in bone loss compared to placebo in postmenopausal women and are currently approved in the European Union for the treatment of postmenopausal osteoporosis. This review outlines the current strategies employed in the use of endocrine therapy in the management and prevention of breast cancer.
Authors:
Ifeyinwa Obiorah; V Craig Jordan
Related Documents :
22069477 - Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a m...
22248347 - Myoid hamartoma of the breast that proved difficult to diagnose: a case report.
22918167 - High proliferation is associated with inferior outcome in male breast cancer patients.
7744577 - Calcium glucarate as a chemopreventive agent in breast cancer.
18946747 - Current research topics in endocrine therapy for breast cancer.
14982837 - Quantitative determination of expression of the prostate cancer protein alpha-methylacy...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review     Date:  2011-10-05
Journal Detail:
Title:  Maturitas     Volume:  70     ISSN:  1873-4111     ISO Abbreviation:  Maturitas     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-07     Completed Date:  2012-03-30     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  7807333     Medline TA:  Maturitas     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  315-21     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
Affiliation:
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, United States. oi3@georgetown.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents, Hormonal / therapeutic use
Aromatase Inhibitors / therapeutic use
Breast Neoplasms / drug therapy*,  prevention & control*
Chemotherapy, Adjuvant
Drug Therapy, Combination
Female
Humans
Selective Estrogen Receptor Modulators / therapeutic use
Tamoxifen / therapeutic use
Grant Support
ID/Acronym/Agency:
P30 CA051008/CA/NCI NIH HHS; P30 CA051008/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/Aromatase Inhibitors; 0/Selective Estrogen Receptor Modulators; 10540-29-1/Tamoxifen
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genome sequencing of mouse induced pluripotent stem cells reveals retroelement stability and infrequ...
Next Document:  [Micro-invasive vulvar Paget's disease and lymph node metastasis: A same disease?].